Please assess the completion status of the following clinical trial:

Trial Title: Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION criteria:~* Males or nonpregnant, non-nursing females \> 2 years old.~* Tuberculin (PPD) skin test reactors at high risk for developing TB but without evidence of active TB. High-risk reactors are defined as:~  1. Household and other close contacts of persons with culture-confirmed TB who are TST-positive as part of a contact investigation conducted within two years of the date of enrollment. Close contact is defined as \> 4 hours in a shared airspace during a one-week period. Among close contacts, a positive TST is defined as \> 5 mm induration after 5 TU of PPD placed intradermally using the Mantoux technique.~ 2. TST converters--converting from a documented negative to positive TST within a two-year period. This is defined as persons with a tuberculin skin test of \> 10 mm within two years of a nonreactive test or persons with an increase of \> 10 mm within a two-year period.~ 3. HIV-seropositive, TST positive (\> 5 mm induration) persons.~ 4. Persons with \> 2 cm2 of pulmonary parenchymal fibrosis on chest X-ray, no prior history of TB treatment, \> 5 mm induration on TST, and 3 sputum cultures negative for M. tuberculosis on final report.~* HIV-seropositive close contacts of persons with culture-confirmed TB, regardless of TST status. In addition, HIV-seropositive close contacts of persons with culture-confirmed TB who have a documented history of completing an adequate course of treatment for active TB or latent TB infection, are also eligible.~* Willing to provide signed informed consent, or parental consent and participant assent.~EXCLUSION criteria:~* Current confirmed culture-positive or clinical TB~* Suspected TB (as defined by the site investigator)~* Tuberculosis resistant to isoniazid or rifampin in the source case~* A history of treatment for \> 14 consecutive days with a rifamycin or \> 30 consecutive days with INH during the previous 2 years.~* A documented history of a completing an adequate course of treatment for active TB or latent TB infection in a person who is HIV-seronegative.~* History of sensitivity/intolerance to isoniazid or rifamycins~* Serum aminotransferase aspartate (AST, SGOT) \> 5x upper limit of normal among persons in whom AST is determined~* Pregnant or nursing females~* Persons currently receiving or planning to receive HIV-1 protease inhibitors or nonnucleoside reverse transcriptase inhibitors in the first 90 days after enrollment.~* Weight \< 10.0 kg

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Daily Isoniazid (Type: ACTIVE_COMPARATOR): Isoniazid (INH) daily for 9 months (240 to 270 total doses).
- Weekly Isoniazid / Rifapentine (Type: EXPERIMENTAL): Isoniazid / Rifapentine (RPT/INH) weekly for 3 months (11 to 12 total doses) given by Directly Observed Therapy (DOT)

Based on this trial design, predict the completion outcome and termination type (if applicable).